{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Widge AT"],"funding":["Intramural NIH HHS","NIAID NIH HHS"],"pagination":["eade4790"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10619166"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(692)"],"pubmed_abstract":["Influenza vaccines could be improved by platforms inducing cross-reactive immunity. Immunodominance of the influenza hemagglutinin (HA) head in currently licensed vaccines impedes induction of cross-reactive neutralizing stem-directed antibodies. A vaccine without the variable HA head domain has the potential to focus the immune response on the conserved HA stem. This first-in-human dose-escalation open-label phase 1 clinical trial (NCT03814720) tested an HA stabilized stem ferritin nanoparticle vaccine (H1ssF) based on the H1 HA stem of A/New Caledonia/20/1999. Fifty-two healthy adults aged 18 to 70 years old enrolled to receive either 20 μg of H1ssF once (<i>n</i> = 5) or 60 μg of H1ssF twice (<i>n</i> = 47) with a prime-boost interval of 16 weeks. Thirty-five (74%) 60-μg dose participan"],"journal":["Science translational medicine"],"pubmed_title":["An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults."],"pmcid":["PMC10619166"],"funding_grant_id":["75N93021C00014","75N93019C00051","Z99 AI999999","P01 AI097092","R01 AI145870"],"pubmed_authors":["Telscher S","Leach K","Patel A","Dropulic LK","Cooper J","Cunningham J","Dobrescu G","Castro M","Strom L","Wang XE","Hatcher C","VRC 321 study team","Arthur A","Holland-Linn J","Costner P","Gollapudi D","Gordon IJ","Adams WC","Hong JS","Casazza J","Banappagari S","Carlton K","Stein JA","Larkin B","Ola AO","Chen GL","Yang RS","Widge AT","Wycuff D","Beck A","McDermott AB","Kueltzo L","Gillespie RA","Ledgerwood JE","Lawlor H","Rothwell RS","Bender M","Williams P","Liang CJ","Vickery K","Novik L","Yi Y","Lee J","Zhao W","Narpala SR","Zhao Z","Gaudinski MR","Berkowitz NM","Koup RA","Gowetski D","Crank MC","Burch E","Hofstetter AR","Requilman L","Hicks R","Chintamani M","Liu JA","Case CL","Mascola JR","Upadhyay S","Pittman I","Apte P","Lei P","Sitar S","Lambert N","Freyn AW","Bahorich J","Yamshchikov G","Trofymenko O","Andrews SF","Coates EE","Saunders J","Demirji J","Kanekiyo M","Shaddeau A","Plummer S","Parker K","Chaudhuri R","Creanga A","Rosales E","Dinh T","Serebryannyy LA","Wu R","Gottumukkala R","Wang X","Horwitz J","Mendoza F","Goh A","Awan SF","Le L","Yang J","Gall JG","O'Connell S","Albright G","Nachbagauer R","Evans C","Manceva S","Li Y","Yang Y","Jones J","Ragunathan R","Hendel CS","Eshun AM","Ivleva V","Houser KV","Burgos Florez MC","Whalen W","Vasilenko O","Vazquez S","Rosado VC","LaPanse A","Palese P","Caringal AT","Nguyen T","Carvalho J","Holman LA","Graham BS","Romaine L","Anderson M","Shadrick W","Misasi J","Lin BC","Schneck N","Cartagena CT","Graves C"],"additional_accession":[]},"is_claimable":false,"name":"An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.","description":"Influenza vaccines could be improved by platforms inducing cross-reactive immunity. Immunodominance of the influenza hemagglutinin (HA) head in currently licensed vaccines impedes induction of cross-reactive neutralizing stem-directed antibodies. A vaccine without the variable HA head domain has the potential to focus the immune response on the conserved HA stem. This first-in-human dose-escalation open-label phase 1 clinical trial (NCT03814720) tested an HA stabilized stem ferritin nanoparticle vaccine (H1ssF) based on the H1 HA stem of A/New Caledonia/20/1999. Fifty-two healthy adults aged 18 to 70 years old enrolled to receive either 20 μg of H1ssF once (<i>n</i> = 5) or 60 μg of H1ssF twice (<i>n</i> = 47) with a prime-boost interval of 16 weeks. Thirty-five (74%) 60-μg dose participan","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2026-05-29T07:14:12.337Z","creation":"2025-04-04T14:35:58.886Z"},"accession":"S-EPMC10619166","cross_references":{"pubmed":["37075129"],"doi":["10.1126/scitranslmed.ade4790"]}}